FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to compounds, which bind with BIR domains of IAP, namely with BIR2 and BIR3 domains. Compounds are represented by formula I 
It is known that apoptotic pathways play critical role in development of cancer, autoimmune disorders and neurodegenerative diseases. Also described is method of obtaining formula I compounds and their pharmaceutical compositions, as well as intermediate compounds for obtaining formula I compounds.
EFFECT: obtaining pharmaceutical compositions for changing apoptotic reactions in cells, which can contribute to treatment of proliferative disorders.
45 cl, 1 dwg, 11 tbl, 23 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS BINDING BTR DOMAIN OF IAP PROTEINS | 2007 |
|
RU2472780C2 |
| COMPOUNDS BOUND WITH BIR DOMAIN OF IAP | 2007 |
|
RU2446170C2 |
| SUBSTITUTED INDOLES | 2000 |
|
RU2255087C2 |
| SUBSTITUTED BICYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHOD OF INHIBITION | 1998 |
|
RU2204557C2 |
| COMPOSITION COMPRISING SILYLATED POLYMERS | 2014 |
|
RU2643990C2 |
| CATALYST SYSTEM | 2003 |
|
RU2326123C2 |
| COMBINATION OF AN MCL-1 INHIBITOR AND A STANDARD DRUG FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | 2018 |
|
RU2792057C2 |
| PRODUCT COMPRISING AT LEAST ONE SUBSTANCE INHIBITING ACTIVITY OF NO-SYNTHASE IN COMBINATION WITH AT LEAST ONE SUBSTANCE INHIBITING ACTIVITY OF PHOSPHOLIPASE A | 2000 |
|
RU2256465C2 |
| ARYL, HETEROARYL AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | 2018 |
|
RU2801278C2 |
| SOMATOSTATIN RECEPTOR ANTAGONISTS AND METHODS FOR USING THEM | 2017 |
|
RU2740464C2 |
